… group, as were the total numbers of hospitalizations for heart failure and … dapagliflozin also
resulted in fewer symptoms of heart failure, as measured on the Kansas City Cardiomyopathy …

… Definite or probable ketoacidosis occurred in 2 patients without heart failure randomly
allocated to placebo; there were no cases of ketoacidosis in the dapagliflozin group. …

… (Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction
Heart Failure) … from long-term use of dapagliflozin in patients with HF with mildly reduced or …

… the effect of dapagliflozin on patients with heart failure, we … mortality, and heart failure-related
hospitalization. Additionally, … and urgent heart failure visits were observed with dapagliflozin …

… safety of dapagliflozin for the management of chronic heart failure. We showed that dapagliflozin
can … death/hospitalization for heart failure, cardiovascular death, and hospitalization for …

… Dapagliflozin in patients with heart failure and reduced … Failure (DAPA-HF) trial included
patients with heart failure and … Dapagliflozin reduced the risk of worsening heart failure events …

… patients with heart failure and a left ventricular ejection fraction of more than 40% to receive
dapagliflozin (… The primary outcome was a composite of worsening heart failure (which was …

… or worsening heart failure when dapagliflozin was initiated in patients with heart failure with
… large absolute risk reductions in patients with a more recent heart failure hospitalization. …

… transporter 2 inhibition with dapagliflozin, in addition to … heart failure to a greater extent
in patients with heart failure with reduced ejection fraction than in those without heart failure …

… Failure), the SGLT2 inhibitor dapagliflozin reduced the incidence of the primary composite
outcome of cardiovascular death or worsening heart failure (HF) in patients … of dapagliflozin …